Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double blinded, placebo-controlled phase Ib clinical trial in adult patients with immune thrombocytopenia. Cross-over treatment will be allowed during the study.


Clinical Trial Description

Approximate 51 to 60 patients will be enrolled in dose escalation (3 cohorts, 8-20 subjects each with the ratio of 3:1 vs Placebo) . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03951623
Study type Interventional
Source Hutchison Medipharma Limited
Contact jiayi Mai
Phone 086-021-20673063
Email Jiayim@hmplglobal.com
Status Recruiting
Phase Phase 1
Start date August 12, 2019
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT02868060 - Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP) Phase 1/Phase 2
Completed NCT04346654 - A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP Phase 2
Terminated NCT01054443 - A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP) Phase 2
Recruiting NCT04915482 - TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2/Phase 3
Completed NCT00344149 - Rituximab as Second Line Treatment for ITP Phase 3
Completed NCT04669600 - A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP) Phase 2
Completed NCT01666795 - Autoantibody Specificity and Response to IVIG in ITP N/A
Active, not recruiting NCT05086744 - Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders Phase 2
Recruiting NCT04968899 - IgIV Plus Prednisone vs High-dose Dexamethasone for ITP Phase 3
Recruiting NCT03975361 - Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE) N/A